Neuro

US MILITARY MEMBERS NOW ELIGIBLE FOR FOCUSED ULTRASOUND TREATMENT REIMBURSEMENT FOR ESSENTIAL TREMOR

Retrieved on: 
Wednesday, January 24, 2024
Woman, MRI, Neuro, Health, Insurance, Military personnel, Head, Quality of life, Tremor, Veteran, Tricare, Magnetic resonance imaging, Essential tremor, Brain, Health insurance

HAIFA, Israel and MIAMI, Jan. 24, 2024 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that effective immediately, 9.5 million US military members and their covered dependents, covered by Tricare are now eligible for coverage reimbursement for focused ultrasound treatment for essential tremor.

Key Points: 
  • Focused ultrasound, pioneered by Insightec , has emerged as a breakthrough incisionless treatment option that provides targeted relief from essential tremor with minimal risks and downtime.
  • Focused ultrasound treatment for essential tremor utilizes magnetic resonance imaging (MRI) guidance to precisely target and ablate a small area of the brain involved in tremor.
  • Tricare, the largest insurance provider for active and retired military personnel, will now cover the costs associated with focused ultrasound treatment for essential tremor for eligible military members and their covered dependents.
  • Military personnel interested in accessing this service can consult their healthcare providers to determine if they are candidates for focused ultrasound treatment for essential tremor.

New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test in Identifying Amyloid and Tau in the Brain

Retrieved on: 
Monday, January 22, 2024
Cerebrospinal fluid, Classification, Pathology, Research, Diagnosis, CSF, Neuro, PET, Immunoassay, University, Amyloid, JAMA, Plasma, AUC, Biomarker, Neurology, Single, Brain, Test management, Blood, Medical imaging

CARLSBAD, Calif., Jan. 22, 2024 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leader in Alzheimer's diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau at residue 217 (pTau217) delivers high diagnostic accuracy and consistency in identifying amyloid and tau in the brain. The article, "Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer's Disease Pathology," was authored by Dr. Nicholas Ashton and colleagues from the University of Gothenburg, Sweden.

Key Points: 
  • With the novel ALZpath pTau217 assay and test, ALZpath is transforming Alzheimer's disease diagnosis and monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide.
  • The ALZpath pTau217 assay showed high diagnostic accuracy in identifying elevated amyloid (AUC, 0.92-0.96; 95%CI 0.89-0.99) and tau (AUC, 0.93-0.97; 95%CI 0.84-0.99) in the brain across all cohorts.
  • Longitudinally, ALZpath's pTau217 test in blood showed an annual increase in individuals with amyloid plaques, with the highest increase observed in those who also had tau pathology.
  • The ALZpath pTau217 test will also be commercially available on other research and diagnostic platforms in support of global accessibility and scalability.

Feel Therapeutics Brings Michel Vounatsos as Chairman Of The Advisory Board, and Secures New Funding to Advance Digital Precision Medicine for Mental Health

Retrieved on: 
Tuesday, January 9, 2024
Neuroscience, Merck & Co., Patient, Therapy, Neuro, SAN, Knowledge, SOSV, CIO, Mental health, Medicine, Digital, Anthemis, Advisory board, Merck, CNS, Nursing

SAN FRANCISCO, Jan. 9, 2024 /PRNewswire-PRWeb/ -- Feel Therapeutics, the Digital Precision Medicine company for mental and behavioral health, announced today that Michel Vounatsos, former CEO of Biogen, has joined as a Chairman of their Advisory Board. Additionally, Feel has secured new funding from Satori Neuro, Metavallon VC, and existing investors such as SOSV, SeedtoB, and others, to fuel its expansion plans. Along with the new funding, Amy Kruse, Chief Investment Officer of Satori Neuro, a pioneering fund focused on mental health, neurotechnology, and human flourishing, has joined the Board of Directors as an observer. These new investors join Feel's existing group of investors, which includes Felicis, SOSV, Anthemis, SeedtoB, and others, that continue to support the company.

Key Points: 
  • SAN FRANCISCO, Jan. 9, 2024 /PRNewswire-PRWeb/ -- Feel Therapeutics , the Digital Precision Medicine company for mental and behavioral health, announced today that Michel Vounatsos, former CEO of Biogen, has joined as a Chairman of their Advisory Board.
  • Feel Therapeutics welcomes Michel Vounatsos, former Biogen CEO, as Advisory Board Chairman.
  • "I am excited to join Feel Therapeutics at this pivotal moment in their journey," said Michel Vounatsos.
  • Feel's approach to precision medicine in mental & behavioral health can transform how we manage, monitor, and treat those conditions.

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, Stem Cells, Neurology, Research, Science, Biotechnology, Virus, Cell, Cancer, Distinguishing, University, Biologic, Dove Medical Press, Neuroscience, UAB Hospital, Emory University, National academy, UAB, Glioblastoma, Radiation therapy, Neuro, Nature Biotechnology, Physician, Birmingham School of Law, Engineering, Neurosurgery, Potyvirus, Harvard Medical School, Supernova, Pulmonology, Hospital, Bangladesh Technical Education Board, University of Groningen, PNAS, Pharmaceutical industry

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

Sector-Leading Companies to Dominate Healthcare Fundraising in New Year Despite Economic Uncertainties

Retrieved on: 
Thursday, January 4, 2024
General Health, Finance, Banking, Health, Professional Services, Ecosystem, Health care, San Francisco Bay Area, Neuro, Metabolism, AI, Initial public offering, VCS, PST, Investment, IPO, PMA, Pharmaceutical industry

We expect significant drip-feeding, consolidations, and shut-downs for companies that have exhausted insider rounds and have not been able to hit significant value inflection points.

Key Points: 
  • We expect significant drip-feeding, consolidations, and shut-downs for companies that have exhausted insider rounds and have not been able to hit significant value inflection points.
  • This trend may involve larger, more mature companies acquiring smaller entities to expand their platforms and geographical footprints.
  • Companies in the computational biology sector, particularly those focused on discovery or development processes, are positioned to sustain increasing investor interest.
  • Despite the likelihood of valuation re-sets for many companies, the underlying strength of the technologies is expected to attract new investor interest, likely led by traditional VCs.

Neuro Synthesist(TM) And Transformational Life Mentor & Coach Brinn Tomes Launches Soul Family Community

Retrieved on: 
Friday, November 24, 2023
Mevalonate pathway, Spirituality, Research, Neuroscience, Happiness, Rewrite, Brain, Neuro, Heart, Anxiety, Perception, Psychology, Automation, Tome, Tourism

As a place to learn, share, and evolve together, the Soul Family is a home for spiritual nomads and those looking to change their perception.

Key Points: 
  • Los Angeles, California--(Newsfile Corp. - November 24, 2023) - Soul Family Community, founded by Neuro Synthesist™ and Transformational Life Mentor & Coach Brinn Tomes, is gearing up for its much-anticipated launch.
  • Brinn Tomes will leverage the Soul Family platform as a centralized hub for insightful talks, transformative courses, engaging workshops, and impactful events.
  • "The Soul Family Community emerges in response to the rapid evolution of humanity, where connections with ourselves, others, and the universe have been eroded.
  • The core of the Soul Family is the community, which helps support each other on the spiritual journey inwards.

Wearable Devices Ramps Up Inventory in Anticipation of its Participation at the 2024 CES Showcase

Retrieved on: 
Wednesday, December 27, 2023
Neuro, Consumer Electronics Show, Apple Watch, Artificial intelligence, Las Vegas Convention Center, CES, WLDS, Consumer electronics

This strategic move aims to meet the anticipated interest following the Company's showcase at the upcoming 2024 Consumer Electronic Show (“2024 CES”) event.

Key Points: 
  • This strategic move aims to meet the anticipated interest following the Company's showcase at the upcoming 2024 Consumer Electronic Show (“2024 CES”) event.
  • As Wearable Devices gears up for the 2024 CES, the Company is proactively increasing the inventory of its flagship product, the Mudra Band.
  • 2024 CES is expected to be a showcase of next-generation innovations in consumer technologies, with Wearable Devices among the leading exhibitors.
  • Asher Dahan, Chief Executive Officer of Wearable Devices, stated, “At the 2024 CES, Wearable Devices will demonstrate the Mudra Band's groundbreaking capabilities in neuro-gestural control.

Trupanion, leading pet medical insurance provider, teams up with renowned animal health experts to raise awareness around pet behavioral health

Retrieved on: 
Thursday, December 7, 2023
Pet, Create, Fear, Adolescence, Cat, Research, Diarrhea, Parent, Trupanion, Health, Doctor of Philosophy, Dog, Anxiety, Sneeze, Socialization, Behavior, Cough, Appetite, CLAS, Veterinary medicine, MRCVS, CVA, Neuroscience, Vomiting, Behavior informatics, Neuro, Environment, Pet industry

The timing of this Trupanion-hosted event coincides with rising veterinary visits related to behavioral concerns in pets.

Key Points: 
  • The timing of this Trupanion-hosted event coincides with rising veterinary visits related to behavioral concerns in pets.
  • During the live event, pet parents received invaluable guidance on enhancing their pets' well-being by understanding and addressing behavioral issues.
  • Here, we share five key takeaways from the event to help pet parents better manage the behavioral health of their beloved furry companions:
    Recognize your pet's normal behavior.
  • Trupanion's Chief Veterinary Officer, Dr. Steve Weinrauch and our panel of animal health experts, are available to share related insights and tips into managing pet behavioral health.

Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, November 29, 2023
Ruff, Biology, University, Pfizer, Corporate Affairs, Biotechnology, Corporate communication, Fred Hutchinson, Drug development, CMC, FC, Molecular biology, Complement component 1s, MGI, Neuro, Therapy, Columbia University, Doctor of Philosophy, Multifocal motor neuropathy, Publication, Patient, Dianthus, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr. Stavenhagen will lead the Company’s discovery and preclinical research and translational science initiatives.

Key Points: 
  • In this role, Dr. Stavenhagen will lead the Company’s discovery and preclinical research and translational science initiatives.
  • “I’m thrilled to welcome Jeff to the Dianthus team as we advance next-generation antibody therapeutics for patients living with severe autoimmune diseases.
  • He was most recently Chief Scientific Officer at Therini Bio, where he directed R&D initiatives leading to the development of a first-in-class monoclonal antibody for the treatment of neurodegenerative diseases.
  • She earned a master’s degree in biotechnology from Northwestern University and a bachelor’s degree in biology from the University of Iowa.

Konica Minolta Healthcare Showcases New Radiography and Ultrasound Solutions at RSNA 2023 That Help Clinicians See What Matters Most

Retrieved on: 
Sunday, November 26, 2023
Carbon, Momentum, Emory Healthcare, Workflow, Instability, Marketing, Health, Ultra, Inflammation, Cartilage, Shoulder, RSNA, Tendon, Joint, University, Annual general meeting, Universal, Clinical research, Pain management, Neuro, Ligament, Partnership, Konica Minolta, Tears, DDR, Imaging, Research, MSK, MD, Doctor of Philosophy, Spine, MBBS, SHR, Medical imaging

Through the company’s leadership advancing the capabilities of primary imaging, these new solutions are designed to enhance the patient experience and help clinicians see what matters most.

Key Points: 
  • Through the company’s leadership advancing the capabilities of primary imaging, these new solutions are designed to enhance the patient experience and help clinicians see what matters most.
  • Konica Minolta will showcase its full line of cutting-edge DR and point-of-care ultrasound systems for radiology departments, imaging centers, group practices and more.
  • Konica Minolta Healthcare offers a broad array of service solutions focused on clinical and operational efficiency throughout the product lifecycle.
  • Konica Minolta builds on the success of AeroRemote Insights with a new release that enables easier management of digital radiography assets.